In recent days, Beilu Pharmaceutical has disclosed the "Announcement on the Acquisition of 80% Equity Interest in Chengde Tianyuan Pharmaceutical Co., Ltd.".The Acquisition Is Progressing Sm...
Recently, Beilu Pharmaceutical received the "Drug Supplementary Application Approval Notice" (Notice Number: 2024B01144) for Gadobenate Dimeglumine Injection issued by the National Medical P...
Recently, Beilu Pharmaceutical announced that it plans to use its own funds to acquire 80% of the equity of Chengde Tianyuan Pharmaceutical Co., Ltd. After the completion of this acquisition, Tianyuan...
Recently, Beilu Pharmaceutical's independently developed exclusive pure Chinese medicine formulation, Jiuwei Zhenxin granules, has been included in the "Double Heart Outpatient Construction S...
The flagship product, Jiuwei Zhenxin Granules, a central nervous system medication developed by Beilu Pharmaceutical, has been included in the "Guidelines for the Diagnosis and Treatment of Ankyl...
Beilu Pharmaceutical's subsidiary, Zhejiang Hichi Pharmaceutical, has recently obtained the certificate of registration for Iohexol API from the Ministry of Food and Drug Safety in Korea.This regi...